December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Jemma Arakelyan: A session on Regional and Socioeconomic Challenges in Oncology at the Global Cancer Movement
Dec 6, 2024, 10:23

Jemma Arakelyan: A session on Regional and Socioeconomic Challenges in Oncology at the Global Cancer Movement

Jemma Arakelyan, Medical Oncologist and the Chief Executive Officer of The Institute of Cancer and Crisis, shared a post on X:

Join us for an engaging session on Regional and Socioeconomic Challenges in Oncology as part of the Global Cancer Movement organized by OncoDaily!

I’m excited to moderate a distinguished line-up of speakers:

  • Roselle De Guzman (Philippines) – Colorectal Cancer in the Philippines
  • Ajay Aggarwal (UK) – Quality and Technology in Colorectal Cancer Surgery
  • Pashtoon Kasi (USA) – Neoadjuvant Immunotherapy for Colorectal Cancers
  • Michael Sapienza (USA) – Project Cure CRC: Ending Colorectal Cancer
  • VERNA VANDERPUYE (Ghana) – Colorectal Cancer Among Women in Ghana
  • Ghassan Abou-Alfa (USA) – Medical Diplomacy in Colorectal Cancer
  • Iga Rawicka(Poland) – Improving Doctor-Patient Communication

Time: 8:20 – 10:40 AM EST.”

Dr. Jemma Arakelyan is a medical oncologist and the Chief Executive Officer of The Institute of Cancer and Crisis. Under her leadership, the Institute is dedicated to raising awareness and providing support for cancer patients facing critical challenges, including those arising from war and pandemics. Currently, she is pursuing her Ph.D. at the City University of Hong Kong, focusing on the development of new anticancer treatments and the mechanisms driving cancer progression. In addition to her academic work, Dr. Arakelyan is actively involved in several scientific organizations, including the European School of Oncology (ESO), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). She also serves as an advisor at the Immune Oncology Research Institute, where they work closely on the clinical development of novel immunotherapeutic agents.